Australia’s PET/CT imaging market is set to grow steadily as the country’s oncology sector leans harder into immunotherapy and precision medicine. That’s the finding from a new GlobalData report, which forecasts the domestic PET/CT systems market will expand at a 5{7729880385ace00763d744956af66a2dd6156639dea227c3bc209fe61f7ca481} compound annual growth rate from 2025 to 2035.
The report says Australia accounted for about 2{7729880385ace00763d744956af66a2dd6156639dea227c3bc209fe61f7ca481} of the Asia-Pacific market for such systems in 2025. Rising cancer cases and the push for more targeted treatments are the main drivers behind the projected growth.
A new research center aims to speed up immunotherapy development
In May 2026, Monash University teamed up with The Alfred hospital to launch the Australian Cancer Research Foundation Centre for Dynamic Immuno-Oncology (CDIO). The facility is designed to strengthen oncological research and accelerate the therapy’s development through better imaging and clinical trials.
Related: Rising arthritis cases boost India hip implant market
The CDIO will use Quadra PET/CT technology alongside immuno-oncology research. The goal is to develop treatment strategies that are more precise and more tailored to individual patients.
Shamreen Parween, a medical devices analyst at GlobalData, said the growing emphasis on early-stage malignancy detection and precision medicine is pushing advanced scanning technology into a bigger role.
“These imaging systems enable comprehensive tumor evaluation, facilitate informed clinical decision-making, and optimize therapeutic planning, thereby contributing to improved clinical outcomes and patient survival,” Parween said. She added that continued investment in diagnostic tools should strengthen the country’s advanced scanning capabilities.
Related: The Best Health Insurance Solutions for 2026: Navigating Your Future Coverage
Translational medicine and clinical trial access get a boost
The collaboration between Monash and The Alfred is expected to open up new opportunities for translational medicine. It should also improve access to clinical studies and support the development of better treatment approaches, according to the report.
Whether the imaging demand drives the push for immune treatments or vice versa is unclear, but the numbers point in one direction.
Parween noted that more advanced adoption of imaging tech will reinforce the nation’s clinical capacity and medical scanning expertise. “In the coming years, these advancements may further elevate the country’s role in the APAC healthcare and imaging landscape,” she said.
Related: What Exactly Is “Healthy News”?
It also says the initiative helps expand Australia’s biomedical research capacity and could attract more investment and partnerships across life sciences and healthcare.
While 2{7729880385ace00763d744956af66a2dd6156639dea227c3bc209fe61f7ca481} of the APAC market sounds small, the nation’s per-capita investment in advanced scanning and immune therapy research is relatively high compared to many regional neighbors. The growth rate, though modest, is steady — and the combination of a new dedicated research center and rising disease incidence suggests that demand for the technology isn’t likely to fade anytime soon.